Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1148/radiol.2482071994
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schueller, G.
Right arrow Articles by Helbich, T. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schueller, G.
Right arrow Articles by Helbich, T. H.
(Radiology 2008;248:406-413.)
© RSNA, 2008


Breast Imaging

US-guided 14-gauge Core-Needle Breast Biopsy: Results of a Validation Study in 1352 Cases1

Gerd Schueller, MD, Sylvia Jaromi, MD, Lothar Ponhold, MD, Michael Fuchsjaeger, MD, Mazda Memarsadeghi, MD, Margaretha Rudas, MD, Michael Weber, MD, Laura Liberman, MD, and Thomas H. Helbich, MD

1 From the Departments of Radiology (G.S., S.J., L.P., M.F., M.W., M.M., T.H.H.) and Pathology (M.R.), Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; and Breast Imaging Section, Memorial Sloan-Kettering Cancer Center, New York, NY (L.L.). From the 2005 RSNA Annual Meeting. Received November 15, 2007; revision requested December 18; revision received January 15, 2008; accepted February 28; final version accepted March 12. Address correspondence to G.S. (e-mail: gerd.schueller{at}meduniwien.ac.at).

Purpose: To retrospectively determine the false-negative rate and the underestimation rate of ultrasonography (US)-guided 14-gauge core-needle breast biopsy (CNB) in nonpalpable lesions, with validation at surgical excision histologic examination and with stability during clinical and imaging follow-up.

Materials and Methods: Informed consent was waived by the institutional review board for this retrospective review of 1352 cases. In 1061 cases, patients underwent surgical excision of lesions visible at US subsequent to US-guided 14-gauge CNB. Follow-up of another 291 benign lesions at US-guided 14-gauge CNB histologic examination showed stability during clinical and imaging follow-up for at least 2 years. US and histologic findings were reviewed and compared for agreement. A false-negative finding was defined as pathologically proved cancer for which biopsy results were benign. The false-negative rate was defined as the proportion of all breast cancers with a diagnosis of benign disease at US-guided 14-gauge CNB. The underestimation rate was defined as an upgrade of a high-risk lesion at US-guided 14-gauge CNB to malignancy at surgery.

Results: US 14-gauge CNB yielded 671 (63.2%) malignant, 86 (8.1%) high-risk, and 304 (28.7%) benign lesions. Each of the 291 benign lesions without surgery remained stable during follow-up. The agreement of US-guided 14-gauge CNB results, surgical excision findings, and follow-up results was 95.8% ({kappa} = 0.93). False-negative findings were encountered in 11 (0.8%) of 1352 cases, and the false-negative rate was 1.6% (11 of 671 malignancies). All false-negative findings were prospectively identified owing to discordance between imaging results and US-guided 14-gauge CNB histologic findings. The underestimation rate was 31.4%.

Conclusion: US-guided 14-gauge CNB is an alternative to surgical excision for assessing nonpalpable breast lesions.

© RSNA, 2008